Below are the most recent publications written about "Interferon Type I" by people in Profiles.
-
Kurt-Jones EA, Gulati S, King M, de Oliveira RB, Rice PA, Zheng B, Shaughnessy J, Edwards JL, Hertzog PJ, Ram S, Golenbock DT. Interferon-epsilon, an estrogen-induced type I interferon, is uniquely exploited by Neisseria gonorrhoeae via effects on sialic acid metabolism. Cell Host Microbe. 2025 Jul 09; 33(7):1133-1145.e4.
-
Arowosegbe A, Guo Z, Vanderleeden E, Derr AG, Wang JP. Janus kinase inhibition prevents autoimmune diabetes in LEW.1WR1 rats. J Autoimmun. 2025 Feb; 151:103358.
-
Chibaya L, DeMarco KD, Lusi CF, Kane GI, Brassil ML, Parikh CN, Murphy KC, Chowdhury SR, Li J, Ma B, Naylor TE, Cerrutti J, Mori H, Diaz-Infante M, Peura J, Pitarresi JR, Zhu LJ, Fitzgerald KA, Atukorale PU, Ruscetti M. Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer. Sci Transl Med. 2024 08 28; 16(762):eadj9366.
-
Bazzone LE, Zhu J, King M, Liu G, Guo Z, MacKay CR, Kyawe PP, Qaisar N, Rojas-Quintero J, Owen CA, Brass AL, McDougall W, Baer CE, Cashman T, Trivedi CM, Gack MU, Finberg RW, Kurt-Jones EA. ADAM9 promotes type I interferon-mediated innate immunity during encephalomyocarditis virus infection. Nat Commun. 2024 May 16; 15(1):4153.
-
Ziegler CGK, Owings AH, Galeas-Pena M, Kazer SW, Miao VN, Navia AW, Tang Y, Bromley JD, Lotfy P, Sloan M, Laird H, Williams HB, George M, Drake RS, Pride Y, Abraham GE, Senitko M, Robinson TO, Diamond G, Lionakis MS, Shalek AK, Ordovas-Montanes J, Horwitz BH, Glover SC. An enhanced IL17 and muted type I interferon nasal epithelial cell state characterizes severe COVID-19 with fungal coinfection. Microbiol Spectr. 2024 Jun 04; 12(6):e0351623.
-
Lin QXX, Rajagopalan D, Gamage AM, Tan LM, Venkatesh PN, Chan WOY, Kumar D, Agrawal R, Chen Y, Fong SW, Singh A, Sun LJ, Tan SY, Chai LYA, Somani J, Lee B, Renia L, Ng LFP, Ramanathan K, Wang LF, Young B, Lye D, Singhal A, Prabhakar S. Longitudinal single cell atlas identifies complex temporal relationship between type I interferon response and COVID-19 severity. Nat Commun. 2024 Jan 18; 15(1):567.
-
Brown Harding H, Kwaku GN, Reardon CM, Khan NS, Zamith-Miranda D, Zarnowski R, Tam JM, Bohaen CK, Richey L, Mosallanejad K, Crossen AJ, Reedy JL, Ward RA, Vargas-Blanco DA, Basham KJ, Bhattacharyya RP, Nett JE, Mansour MK, van de Veerdonk FL, Kumar V, Kagan JC, Andes DR, Nosanchuk JD, Vyas JM. Candida albicans extracellular vesicles trigger type I IFN signalling via cGAS and STING. Nat Microbiol. 2024 Jan; 9(1):95-107.
-
Dong M, Fitzgerald KA. STING channels its proton power. Mol Cell. 2023 10 05; 83(19):3402-3403.
-
Devarajan P, Vong AM, Castonguay CH, Silverstein NJ, Kugler-Umana O, Bautista BL, Kelly KA, Luban J, Swain SL. Cytotoxic CD4 development requires CD4 effectors to concurrently recognize local antigen and encounter type I IFN-induced IL-15. Cell Rep. 2023 10 31; 42(10):113182.
-
Humphries F, Shmuel-Galia L, Jiang Z, Zhou JY, Barasa L, Mondal S, Wilson R, Sultana N, Shaffer SA, Ng SL, Pesiridis GS, Thompson PR, Fitzgerald KA. Targeting STING oligomerization with small-molecule inhibitors. Proc Natl Acad Sci U S A. 2023 08 15; 120(33):e2305420120.